Monoclonal Antibody Therapeutics
•150 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (150)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Lilly relies on monoclonal antibody therapeutics across indications.
|
$931.28B |
$984.94
+0.79%
|
|
JNJ
Johnson & Johnson
Johnson & Johnson's portfolio includes multiple monoclonal antibody therapeutics (e.g., DARZALEX, CARVYKTI, TECVAYLI, TALVEY) across oncology and immunology.
|
$581.89B |
$241.55
-0.20%
|
|
ABBV
AbbVie Inc.
AbbVie directly commercializes monoclonal antibody therapeutics (e.g., Skyrizi) as a core immunology asset.
|
$388.26B |
$219.69
-2.52%
|
|
AZN
AstraZeneca PLC
AZN develops monoclonal antibody therapeutics across oncology and immunology.
|
$294.35B |
$189.92
-1.34%
|
|
MRK
Merck & Co., Inc.
Keytruda and other antibody therapies place Merck in monoclonal antibody therapeutics.
|
$286.95B |
$115.58
-0.29%
|
|
AMGN
Amgen Inc.
Amgen's portfolio includes monoclonal antibody therapeutics such as Repatha and tezepelumab (TEZSPIRE).
|
$197.20B |
$366.31
-0.40%
|
|
GILD
Gilead Sciences, Inc.
Trodelvy’s antibody component and other cancer therapies align with Monoclonal Antibody Therapeutics.
|
$179.89B |
$144.97
+0.40%
|
|
PFE
Pfizer Inc.
Monoclonal antibody therapeutics represent a major therapeutic modality in Pfizer's portfolio and oncology pipeline.
|
$151.13B |
$26.59
-1.01%
|
|
BMY
Bristol-Myers Squibb Company
Opdivo is a monoclonal antibody immuno-oncology therapy, a core direct product in BMY's Growth Portfolio.
|
$120.27B |
$59.08
+0.21%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Regeneron’s core business centers on monoclonal antibody therapeutics (e.g., Dupixent, Libtayo).
|
$78.38B |
$746.12
-0.07%
|
|
TAK
Takeda Pharmaceutical Company Limited
Entrvyo/vedolizumab and other monoclonal antibody therapies place Takeda in Monoclonal Antibody Therapeutics.
|
$55.51B |
$17.77
-0.03%
|
|
ZTS
Zoetis Inc.
Zoetis employs monoclonal antibodies for OA pain and dermatology therapies (e.g., Librela, Solensia, Cytopoint), defining a core Monoclonal Antibody Therapeutics product line.
|
$50.95B |
$115.67
+0.18%
|
|
ARGX
argenx SE
argenx's core offerings are monoclonal antibody therapeutics, including VYVGART.
|
$42.75B |
$700.61
-1.16%
|
|
ONC
BeOne Medicines Ltd.
TEVIMBRA is a monoclonal antibody therapy, placing the company in monoclonal antibody therapeutics.
|
$31.46B |
$284.30
-0.35%
|
|
BIIB
Biogen Inc.
Biogen's portfolio includes monoclonal antibody therapeutics (e.g., LEQEMBI) as a core modality.
|
$26.63B |
$181.51
-1.83%
|
|
BNTX
BioNTech SE
The company develops monoclonal antibody therapeutics (including bispecifics) for cancer, a core product area.
|
$21.93B |
$91.25
+1.28%
|
|
ROIV
Roivant Sciences Ltd.
Immunovant's FcRn-targeting therapies (e.g., IMVT-1402, batoclimab) are monoclonal antibody therapeutics.
|
$19.52B |
$28.08
-1.65%
|
|
INCY
Incyte Corporation
Monoclonal Antibody Therapeutics is a direct product modality for Monjuvi (tafasitamab) and similar antibody-based cancer therapies.
|
$18.17B |
$92.55
+0.56%
|
|
GMAB
Genmab A/S
Genmab develops and commercializes monoclonal antibody therapeutics (e.g., antibody-based oncology medicines).
|
$16.78B |
$26.14
-1.64%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab is an antibody-based therapeutic, aligning with Monoclonal Antibody Therapeutics as a core modality.
|
$12.00B |
$16.11
+4.20%
|
|
RDY
Dr. Reddy's Laboratories Limited
Monoclonal antibody therapeutics emphasis via biosimilar strategies (e.g., abatacept, rituximab, pembrolizumab collaboration).
|
$11.76B |
$14.13
-1.53%
|
|
ELAN
Elanco Animal Health Incorporated
Monoclonal Antibody Therapeutics platform (CPMA and IL‑31 related programs) constitutes a key technology and product approach.
|
$11.40B |
$22.95
+1.21%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a monoclonal antibody therapeutic, aligning with Monoclonal Antibody Therapeutics.
|
$10.85B |
$178.57
-0.97%
|
|
MRUS
Merus N.V.
Core product category: monoclonal antibody therapeutics used in cancer indications.
|
$6.81B |
$90.00
|
|
APGE
Apogee Therapeutics, Inc.
Directly develops and manufactures monoclonal antibody therapeutics (APG777, APG808, APG990).
|
$4.91B |
$71.94
-2.14%
|
|
TGTX
TG Therapeutics, Inc.
BRIUMVI is TG Therapeutics' flagship monoclonal antibody therapeutic (anti-CD20) for relapsing MS, the core product driving revenue and growth.
|
$4.44B |
$27.98
+3.84%
|
|
IMVT
Immunovant, Inc.
IMVT-1402 and batoclimab are monoclonal antibodies targeting FcRn, aligning with monoclonal antibody therapeutics.
|
$4.28B |
$24.41
-2.34%
|
|
SRRK
Scholar Rock Holding Corporation
Directly develops and markets monoclonal antibody therapeutics (apitegromab, SRK-439, SRK-181) across SMA, obesity/metabolic, and oncology.
|
$4.08B |
$39.99
-4.33%
|
|
CNTA
Centessa Pharmaceuticals plc
LockBody is an antibody-based platform; its advances map to 'Monoclonal Antibody Therapeutics'.
|
$3.53B |
$26.36
-3.18%
|
|
KNSA
Kiniksa Pharmaceuticals, Ltd.
KPL-387 is a monoclonal antibody targeting IL-1R1, placing the pipeline in monoclonal antibody therapeutics.
|
$3.47B |
$45.78
-0.62%
|
|
DNTH
Dianthus Therapeutics, Inc.
Lead product is a monoclonal antibody therapeutic targeting active C1s, a core product category.
|
$3.34B |
$77.84
-3.09%
|
|
SYRE
Spyre Therapeutics, Inc.
Spyre's pipeline comprises engineered monoclonal antibodies (SPY001/SPY002/SPY003) targeting α4β7, TL1A, and IL-23 for IBD and RA.
|
$3.10B |
$39.81
-1.47%
|
|
VRDN
Viridian Therapeutics, Inc.
Lead programs Veligrotug and VRDN-003 are monoclonal antibodies targeting IGF-1R, i.e., Monoclonal Antibody Therapeutics.
|
$2.74B |
$28.67
+0.92%
|
|
ALMS
Alumis Inc. Common Stock
Lonigutamab is a monoclonal antibody therapy, a direct product in the biopharma pipeline.
|
$2.58B |
$24.80
-0.90%
|
|
VERA
Vera Therapeutics, Inc.
Atacicept is a biologic therapeutic (dual BAFF/APRIL inhibitor) with a monoclonal antibody–like profile, placing Vera's lead program under Monoclonal Antibody Therapeutics.
|
$2.55B |
$39.94
-3.00%
|
|
BEAM
Beam Therapeutics Inc.
BEAM-103 involves an anti-CD117 monoclonal antibody; includes Monoclonal Antibody Therapeutics as part of its conditioning strategy.
|
$2.55B |
$25.17
-1.64%
|
|
RCUS
Arcus Biosciences, Inc.
Domvanalimab is a monoclonal antibody therapeutic, placing Arcus in the Monoclonal Antibody Therapeutics category.
|
$2.37B |
$21.95
-3.30%
|
|
RARE
Ultragenyx Pharmaceutical Inc.
UX143 is a monoclonal antibody; Ultragenyx' portfolio includes monoclonal antibody therapeutics (Crysvita, Evkeeza, UX143).
|
$2.06B |
$21.32
-1.80%
|
|
SNDX
Syndax Pharmaceuticals, Inc.
Niktimvo axatilimab-csfr is a monoclonal antibody therapy, fitting Monoclonal Antibody Therapeutics.
|
$2.04B |
$23.53
-1.92%
|
|
ZLAB
Zai Lab Limited
Significant monoclonal antibody therapeutics activity across oncology/immunology assets.
|
$2.03B |
$18.34
-2.81%
|
|
ADPT
Adaptive Biotechnologies Corporation
Monoclonal Antibody Therapeutics tag aligns with autoreactive TCR targeting and antibody programs.
|
$2.01B |
$13.17
+5.78%
|
|
CLDX
Celldex Therapeutics, Inc.
Barzolvolimab is a therapeutic monoclonal antibody, placing Celldex in Monoclonal Antibody Therapeutics.
|
$1.96B |
$29.50
-1.27%
|
|
IMNM
Immunome, Inc.
Antibody-based therapeutics component of ADCs justifies Monoclonal Antibody Therapeutics tagging.
|
$1.87B |
$20.37
-2.95%
|
|
ANAB
AnaptysBio, Inc.
Lead programs are monoclonal antibody therapeutics (antibodies such as rosnilimab, ANB033, ANB101).
|
$1.79B |
$64.87
+1.69%
|
|
ZYME
Zymeworks Inc.
Company develops monoclonal antibody therapeutics as a core modality.
|
$1.71B |
$22.89
-1.46%
|
|
OGN
Organon & Co.
Monoclonal antibody therapeutics including Emgality marketed within Organon's portfolio.
|
$1.65B |
$6.35
+0.32%
|
|
OCS
Oculis Holding AG
OCS-02 Licaminlimab is an antibody-based therapeutic (monoclonal antibody therapeutics).
|
$1.42B |
$25.48
-5.98%
|
|
NKTR
Nektar Therapeutics
NKTR-0165 is a monoclonal antibody therapeutic (TNFR2 agonist), aligning with Monoclonal Antibody Therapeutics.
|
$1.39B |
$73.30
+4.17%
|
|
VIR
Vir Biotechnology, Inc.
VIR's antibody-based approaches include monoclonal antibody therapeutics targeting cancer antigens.
|
$1.29B |
$9.26
-2.37%
|
|
TRML
Tourmaline Bio, Inc.
Pacibekitug is a monoclonal antibody therapeutic targeting IL-6, fitting Monoclonal Antibody Therapeutics.
|
$1.23B |
$47.98
+0.01%
|
|
KOD
Kodiak Sciences Inc.
Lead assets are monoclonal antibody therapeutics designed for retinal disease, aligning with Monoclonal Antibody Therapeutics.
|
$1.22B |
$23.19
-2.52%
|
|
NRIX
Nurix Therapeutics, Inc.
The narrative references antibody therapies in addition to small molecule degraders, aligning with Monoclonal Antibody Therapeutics.
|
$1.16B |
$15.03
-3.75%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Lead product is a monoclonal antibody–type therapeutic, aligning with Monoclonal Antibody Therapeutics.
|
$1.05B |
$19.16
-0.23%
|
|
ABCL
AbCellera Biologics Inc.
Company is developing monoclonal antibody therapeutics through wholly-owned programs ABCL635 and ABCL575.
|
$1.04B |
$3.50
+0.72%
|
|
ERAS
Erasca, Inc.
ERAS-12 is an EGFR biparatopic antibody, constituting Monoclonal Antibody Therapeutics.
|
$1.02B |
$3.58
+6.07%
|
|
BHVN
Biohaven Ltd.
BHVN's Trop2 ADC program aligns with Monoclonal Antibody Therapeutics as a core oncology modality.
|
$1.01B |
$9.58
-3.33%
|
|
ZBIO
Zenas BioPharma, Inc.
Obexelimab is a monoclonal antibody therapeutic developed by the company.
|
$1.01B |
$23.95
-2.24%
|
|
INBX
Inhibrx Biosciences, Inc.
Monoclonal antibody therapeutics addressing cancer targets with multivalent formats.
|
$995.73M |
$68.52
-1.13%
|
|
AVBP
ArriVent BioPharma, Inc. Common Stock
ADC programs involve monoclonal antibody components; ARR-217 implies monoclonal antibody therapeutics as part of the ADC strategy.
|
$986.62M |
$23.91
-0.79%
|
|
RAPT
RAPT Therapeutics, Inc.
RPT904 is a monoclonal antibody therapeutic, fitting Monoclonal Antibody Therapeutics.
|
$959.52M |
$57.99
-0.04%
|
|
OMER
Omeros Corporation
Narsoplimab and zaltenibart OMS906 are monoclonal antibody therapeutics, a core product class for Omeros.
|
$958.91M |
$13.94
-1.10%
|
|
CMPX
Compass Therapeutics, Inc.
Company develops Monoclonal Antibody Therapeutics for oncology applications.
|
$923.10M |
$5.18
-0.19%
|
|
OPK
OPKO Health, Inc.
ModeX antibody therapies fall under monoclonal antibody therapeutics.
|
$913.56M |
$1.20
+3.02%
|
|
XNCR
Xencor, Inc.
Core output includes engineered monoclonal antibody therapeutics via the XmAb platform.
|
$856.93M |
$12.03
+3.62%
|
|
JANX
Janux Therapeutics, Inc.
Therapies revolve around monoclonal antibody-based modalities (including bispecific antibodies).
|
$816.81M |
$13.58
-2.62%
|
|
CGEM
Cullinan Therapeutics, Inc.
Antibody-based therapeutics (monoclonal antibodies) are a direct product modality for CLN-978 and velinotamig.
|
$796.94M |
$13.49
-3.26%
|
|
CTMX
CytomX Therapeutics, Inc.
PROBODY therapeutics are monoclonal antibody–based biologics, aligning with Monoclonal Antibody Therapeutics.
|
$771.79M |
$4.67
-4.00%
|
|
ATXS
Astria Therapeutics, Inc.
Astria Therapeutics develops monoclonal antibody therapeutics (navenibart and STAR-0310).
|
$709.95M |
$12.56
-0.16%
|
|
ABSI
Absci Corporation
Internal programs ABS-101/ABS-201/ABS-301/ABS-501 are antibody-based therapeutics targeting oncology and immunology, aligning with Monoclonal Antibody Therapeutics.
|
$559.21M |
$3.87
+3.34%
|
|
VNDA
Vanda Pharmaceuticals Inc.
Imsidolimab is a monoclonal antibody therapeutic targeting IL-36R for generalized pustular psoriasis.
|
$520.64M |
$8.79
-5.38%
|
|
ANNX
Annexon, Inc.
Annexon's lead programs are monoclonal antibody therapeutics (ANX005, ANX009) targeting C1q.
|
$515.37M |
$4.67
-6.87%
|
|
ADCT
ADC Therapeutics S.A.
ZYNLONTA uses a monoclonal antibody as its targeting moiety, fitting Monoclonal Antibody Therapeutics.
|
$511.61M |
$4.12
-5.17%
|
|
UPB
Upstream Bio, Inc.
Verekitug is a monoclonal antibody therapeutic targeting the TSLP receptor, directly aligning with Monoclonal Antibody Therapeutics.
|
$497.58M |
$9.23
-2.17%
|
|
PRTA
Prothena Corporation plc
Prothena's core assets are monoclonal antibody therapeutics (PRX012, PRX019, PRX123, etc.) across neurodegenerative diseases, including Alzheimer's and other indications.
|
$495.77M |
$9.20
-1.18%
|
|
EBS
Emergent BioSolutions Inc.
Ebanga is a monoclonal antibody therapeutic developed by Emergent for Ebola; this aligns with the Monoclonal Antibody Therapeutics investable theme.
|
$423.84M |
$8.05
-0.92%
|
|
PRTC
PureTech Health plc
LYT-200 is a monoclonal antibody therapeutic, a core biologics modality.
|
$398.40M |
$17.16
+1.75%
|
|
YMAB
Y-mAbs Therapeutics, Inc.
DANYELZA (naxitamab-gqgk) is a monoclonal antibody therapeutic.
|
$389.89M |
$8.61
|
|
ITOS
iTeos Therapeutics, Inc.
Belrestotug is a monoclonal antibody targeting TIGIT, indicating direct production of monoclonal antibody therapeutics.
|
$388.48M |
$10.15
|
|
ACRS
Aclaris Therapeutics, Inc.
Bosakitug and other assets are monoclonal antibody therapeutics, matching Monoclonal Antibody Therapeutics.
|
$383.54M |
$3.56
+1.28%
|
|
MNPR
Monopar Therapeutics Inc.
MNPR-101 is a humanized monoclonal antibody targeting uPAR, fitting Monoclonal Antibody Therapeutics.
|
$380.87M |
$56.59
-8.33%
|
|
STTK
Shattuck Labs, Inc.
SL-325 is a monoclonal antibody targeting DR3, making Monoclonal Antibody Therapeutics a direct product category.
|
$379.05M |
$5.99
-2.37%
|
|
SIGA
SIGA Technologies, Inc.
SIGA's pipeline includes fully human monoclonal antibodies licensed from Vanderbilt, aligning with Monoclonal Antibody Therapeutics.
|
$376.68M |
$5.25
-3.93%
|
|
VIGL
Vigil Neuroscience, Inc.
Direct product: Vigil's lead program iluzanebart is a fully human monoclonal antibody TREM2 agonist, categorizing under Monoclonal Antibody Therapeutics.
|
$375.71M |
$8.05
|
|
FBRX
Forte Biosciences, Inc.
FB102 is a monoclonal antibody therapeutic targeting CD122, directly matching Monoclonal Antibody Therapeutics.
|
$332.45M |
$26.67
-1.66%
|
|
ACIU
AC Immune S.A.
Monoclonal Antibody Therapeutics – AC Immune develops conformation-specific monoclonal antibodies via SupraAntigen platforms.
|
$304.19M |
$3.01
+0.33%
|
|
CNTX
Context Therapeutics Inc.
CTX's products are therapeutic antibodies (monoclonal antibody therapeutics) used for cancer.
|
$301.41M |
$3.36
+8.74%
|
|
ANL
Adlai Nortye Ltd.
ANL’s antibody-based therapeutics position the company within Monoclonal Antibody Therapeutics as a related category.
|
$293.06M |
$7.86
-5.98%
|
|
IVVD
Invivyd, Inc.
Invivyd's PEMGARDA and pipeline candidate VYD2311 are monoclonal antibody therapeutics targeting evolving viral threats, making Monoclonal Antibody Therapeutics the core product category.
|
$285.94M |
$2.29
-3.99%
|
|
ZURA
Zura Bio Limited
Crebankitug and torudokimab are monoclonal antibodies in Zura Bio's pipeline (Monoclonal Antibody Therapeutics).
|
$261.37M |
$4.01
-0.25%
|
|
VYGR
Voyager Therapeutics, Inc.
VY7523 is a monoclonal antibody targeting tau, category: Monoclonal Antibody Therapeutics.
|
$247.70M |
$4.46
-8.52%
|
|
RZLT
Rezolute, Inc.
Ersodetug is a human monoclonal antibody designed to treat HI by modulating insulin signaling, representing a monoclonal antibody therapeutic product.
|
$240.63M |
$2.60
-13.91%
|
|
ALEC
Alector, Inc.
Latozinemab and AL101 are monoclonal antibody therapeutics in the pipeline.
|
$240.13M |
$2.21
-0.90%
|
|
SLRN
Acelyrin, Inc.
Lonigutamab is a monoclonal antibody therapeutic (IGF-1R) being developed as a treatment for TED, aligning with Monoclonal Antibody Therapeutics.
|
$228.61M |
$2.27
|
|
SRZN
Surrozen, Inc.
Company develops monoclonal antibody therapeutics targeting tissue-specific Wnt signaling.
|
$216.06M |
$25.00
-3.47%
|
|
RNA
Avidity Biosciences, Inc.
Monoclonal Antibody Therapeutics: uses antibody component for targeting in the AOC platform.
|
$213.33M |
$13.76
-5.36%
|
|
CGEN
Compugen Ltd.
COM701 and GS-0321 are monoclonal antibody therapeutics in development, aligning with Monoclonal Antibody Therapeutics.
|
$209.53M |
$2.24
+1.36%
|
|
AVTX
Avalo Therapeutics, Inc.
AVTX-9.00 is an anti-IL-1β monoclonal antibody, directly fitting Monoclonal Antibody Therapeutics.
|
$207.81M |
$15.79
-5.51%
|
|
CHRS
Coherus Oncology, Inc.
LOQTORZI is a differentiated PD-1 monoclonal antibody and commercial oncology product, aligning with Monoclonal Antibody Therapeutics.
|
$197.02M |
$1.63
-3.55%
|
|
STRO
Sutro Biopharma, Inc.
ADC therapies are a form of monoclonal antibody–based therapeutics, aligning with Sutro's antibody-drug conjugate products.
|
$195.66M |
$23.18
-5.19%
|
|
ADAG
Adagene Inc.
Core focus on monoclonal antibody therapeutics (ADG126 and related SAFEbody-based antibodies).
|
$194.56M |
$4.26
+19.66%
|
Showing page 1 of 2 (150 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
